Abstract. KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently carried out in Japan. Single doses of KRN568, ranging from 25 mg to 400 mg, were orally administered to 6 healthy male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8 ng/ml) compared to the other 5 individuals (Cmax 6.5±2.2 and 7.4±1.6 ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125 pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34±6 to 63±3 pg/ml) after oral administration of 400 mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound.

Key words: Calcimimetics, Calcium-sensing receptor, Gastrin
of time. The phase 1 clinical trials of KRN568 have been finished recently in Japan and confirmed the clinical usefulness and overall safety of this compound with Japanese population. Our concern that KRN568 might induce enhanced secretion of gastrin in the clinical situation prompted us to study the gastrin levels after its administration to the participants in the phase 1 trials who gave their informed consent.

Subjects and Methods

Clinical trial

The phase 1 study was designed as a single-dose oral, open-labeled and stepwise dosing protocol from 25 to 400 mg. Each of six healthy male volunteers, aged from 20 to 25, was subjected to this trial study both at fasting and after meal ("non-fasting" in Figs. 2-4 and Table 1). Plasma samples were taken before dosing and 0.5, 1, 2, 4, 8, 12, 24 and 48 hr after dosing. Portions of those samples remained after finishing the complete phase I study including biochemical parameters were utilized for immunoradiometric assay of gastrin (Gastrin RIA kit 2, Dainabot Co., Ltd., Tokyo).

Genotyping of Cytochrome P450

Genomic DNA was isolated from peripheral lymphocytes of each subjects. The genotype of CYP2D6 was determined according to the method of Fukuda et al. [4]. CYP2D6*10 (exon1: 188C→T, exon9: 4268G→C) and CYP2D6*2 (exon6: 2938C→T) were detected by cleavage of PCR products by restriction enzyme Hph I, Hha I and Ban II, respectively. Xba I restriction fragment length polymorphism (RFLP) analysis was performed to detect CYP2D6*5, which lacks one entire allele of CYP2D6 (Fig. 1), according to the method of Steen et al. [5]. CYP2C19*1 and two defective forms, CYP2C19*2 and CYP2C19*3, were identified by PCR-RFLP analysis previously described by de Morais et al. [6] with minor modifications. After PCR amplification using specific primers, each product was digested with restriction enzymes Msp I and Bam HI [7]. All analyses were performed with informed consent.

Measurement of plasma KRN568 concentrations

Portions of plasma samples collected before dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hr after dosing were used for pharmacokinetics of KRN568. The concentrations of KRN568 and its metabolites were measured by gas chromatography and mass spectrophotometry in the Mitsubishi-Kagaku Bioclinical Laboratory Inc., Tokyo.

Results and Discussion

Calcium is known to increase serum gastrin levels by activation of neural pathways or direct stimulation of antral G-cells. The recent discovery of membrane-associated Ca-sensing receptors (CaR) has opened the way to the study of the mechanism whereby calcium modulates various physiological cellular events [8]. Ray et al. have shown that the

Fig. 1. Xba I-RFLP analysis of genomic DNA. Southern blotting was carried out using CYP2D6 cDNA as a probe (lanes: M for the size marker and 1 to 4 for subject numbers). Since the restriction fragment of allele CYP2D6 includes the preceding pseudogenes CYP2D8 and CYP2D7, it was detected as 29-kb bands (subjects #1 to #3). The deletion of an entire CYP2D6, the allele CYP2D6*5, resulted in a 13-kb fragment indicating only the chain of the pseudogenes detected by the same probe (subjects #2 and #4). A 44-kb fragment was detected in subject #4 representing CYP2D6*10, the product of which has the weakest enzyme activity [19]. Thus, the genotype of the poor metabolizer in our study is *5/*10.
Fig. 2. Hypocalcemic effects of KRN568 in phase 1 clinical trial. Twenty-five to 400 mg of KRN568 was administered to 6 healthy volunteers in the phase 1 clinical trial (for panels A and B, △ 25 mg; ▲ 50 mg; ○ 100 mg; ● 200 mg; ○○○ 400 mg, fasting; ●●● 400 mg, non-fasting; Data represent means ± SE). The effect of calcimimetic was evident in terms of decreases both in plasma PTH (panel A) and ionized calcium levels (panel B) at 400 mg. One of the subjects tested was a poor metabolizer (PM) showing remarkably higher concentrations of KRN568 after oral administration than the other 5 normal metabolizers (NM) (panel C, △ PM, fasting; ▲ PM, non-fasting; ○○○ NM, fasting; ●●● NM, non-fasting; ○○○ NM, 200 mg; Data of 5 NMs represent averages).
extracellular CaR identical to that of parathyroid cells is expressed on human antral gastrin cells by reverse transcription PCR, immunocytochemistry and Western blots of whole cell lysates with a specific antibody [3]. They have also shown that an increase in extracellular calcium levels stimulates gastrin release in a concentration-dependent manner, indicating that the activation of CaR may explain the acid rebound phenomenon associated with calcium-containing antacid preparations. Transcripts similar to those in the parathyroid and kidney have been detected in rat gastric mucosal poly A+ RNA by Cheng et al., who suggest that the effects of extracellular Ca²⁺ on gastric function may be attributable to activation of CaR [9].

Calcimimetics that interact with CaR to enhance calcium action on CaR have been developed by NPS Pharmaceuticals (Salt Lake City, UT, USA) and Kirin Brewery Co. (Tokyo, Japan) and have been studied extensively for their clinical usefulness as well as safety [10]. Clinical application has already been successfully started in a patient with parathyroid cancer [11], those with primary hyperparathyroidism [12] and hemodialysis patients with secondary hyperparathyroidism [13]. Recently, phase 1 clinical trial of KRN568 has been conducted with healthy male volunteers in Japan. Various amounts of KRN568 from 25 mg to 400 mg were administered to each of six healthy male volunteers at fasting and after meal. Since the hypocalcemic effect of the compound was variable depending on the individuals tested in the single-dose clinical trial performed in the United States (personal communication with NPS Pharmaceuticals), polymorphism of cytochrome P450 was suspected as a cause, which has turned out to be the case in our study. Genotyping for CYP2D6 and 2C19, which are the predominant enzyme and bypass enzyme metabolizing KRN568, respectively, was thus carried out with all volunteer participants after obtaining fully informed consent. It was revealed that KRN568 had considerable ability to suppress PTH secretion and to decrease serum calcium levels (Fig. 2, panels A and B), but that no specific, serious and long-lasting side effects were observed during the period of administration and the subsequent one month (details to be published elsewhere). Increased serum phosphate, urinary excretion of calcium and decreased urinary excretion of phosphate were observed in parallel, which are compatible with suppression of PTH (data not shown). One subject was revealed to have CYP2D6 gene mutation (2D6*5/*10) and his poor metabolizing capacity for KRN568 was confirmed by detection of more than 10-fold high concentrations of plasma KRN568 (Cmax 90.8 at fasting and 83.8 ng/ml after meal) compared to the other five individuals (Cmax 6.5±2.2 and 7.4±1.6 ng/ml, respectively) after administration of 400 mg (Fig. 2, panel C and Table 1). This mutation, however, causes weaker enzyme activity only for KRN568 but not for any other substrates. Plasma gastrin levels showed mild but apparent increases (from 30 to 125 pg/ml) in this particular case, while there were no significant increases in the other five people (from 34 ± 6 to 63 ± 3 pg/ml) after administration of KRN568 (Fig. 3, panels A and B). The difference between these groups is not statistically significant because of the single poor metabolizer, but reasonably significant because an intravenous calcium infusion test, which is employed to detect an exaggerated response in gastrinoma patients, usually shows minimal or less than 50% increase over basal values when employed in normal subjects [14]. Plasma PTH and serum calcium levels were suppressed for longer duration in the poor metabolizer than in the normal ones (Fig. 4, panels A and B). This was compatible with the difference of pharmacokinetics between the two groups. These observations suggested that calcium-induced stimula-

| Table 1. Pharmacokinetic parameters of KRN568 when 400 mg was administered. |
|-----------------|-----------------|-----------------|-----------------|
|                 | Cmax (ng/ml)    | AUC (ng-hr/ml)  | tmax (hr)       |
| Normal metabolizer (n=5) |                 |                 |                 |
| Fasting         | 6.4±1.6         | 40.5±8.6        | 2.4±0.6         |
| Non-fasting     | 7.4±1.1         | 44.0±5.3        | 2.4±0.5         |
| Poor metabolizer (n=1) |                 |                 |                 |
| Fasting         | 90.8            | 700             | 2               |
| Non-fasting     | 83.8            | 689             | 3               |
tion of human gastrin secretion in vivo was mediated by a mechanism involving CaR. Since PTH levels were suppressed by a much smaller amount of KRN568 as low as 25 mg (data not shown), the CaR-mediated mechanism of parathyroid glands seemed to be more sensitive to the changes in extracellular calcium concentration than that of antral gastrin cells.

Although KRN568 has been proved a safe agent for clinical use and no direct GI side effects have been reported with this compound in any of the previous papers [15], there is the possibility that it can cause continuous gastrin hypersecretion in poor metabolizers when used frequently in large doses over a long period. The poor metabolizer in our study harbors one allele producing an enzyme with the weakest activity (CYP2D6*10) and lacks another allele encompassing the entire region of the CYP2D6 gene (CYP2D6*5) (Fig. 1, subject #4). Incidence of CYP2D6*5/*10 in the Japanese population is 3%, while those of alleles CYP2D6*5 and CYP2D6*10 are 4.5% and 38.1%, respectively [16]. Because the incidence of slow metabolizers in the Japanese population is far less than in Caucasians [17], these

---

**Fig. 3.** Enhancement of gastrin secretion by KRN568 in a poor metabolizer. Serum gastrin levels were determined after administration of 400 mg KRN568 to 5 normal metabolizers (panel A, ○--○ fasting; ●--● non-fasting, Data represent means ± SE ) and one poor metabolizer (panel B, △--△ fasting; ▲--▲ non-fasting) as described in the text. Although they fluctuated within normal range in either case, the serum levels of gastrin increased reaching a peak at 4 hrs after administration.
considerations may not be so serious but they are still worthy of note. In addition, it may be noteworthy that cimetidine or ranitidine, H2-blockers inhibiting CYP2D6, has a good chance to be effectively administered to hypercalcemic patients to relieve abdominal discomfort, but that simultaneous use with KRN568 will result in poor degradation of both drugs [18]. Calcimimetics of the next generation which are not affected by polymorphism of metabolic enzymes are awaited to achieve clinical satisfaction.

Acknowledgements

We thank Y. Furuya, J. Ishida, H. Murakoshi, M. Nakagawa, and J. Koumegawa, Kirin Brewery Company, Tokyo, for organizing the phase 1 clinical trial and their assistance in performing the biochemical and pharmacological measurements.


